Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Contraceptive Efficacy Study of Ovaprene
Recruiting
This will be a multi-center, single arm, open-label study of Ovaprene, a non-hormonal intravaginal ring, to investigate the contraceptive effectiveness, safety and acceptability of Ovaprene.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
02/25/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Contraception
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
Recruiting
The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). The names of the study intervention involved in this study is: • Supervised circuit training (aerobic and resistance exerc... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: PROSTATE CANCER, Metastatic Prostate Cancer, Metastatic Prostate Carcinoma
Doulas As Environmental Educators and Partners Study
Recruiting
The aims of this project are: Aim 1: Determine the extent to which an environmental health literacy educational intervention designed for doulas improves their environmental health literacy of endocrine disrupting chemicals (EDCs) in personal care products. Hypothesis 1a. Doulas who participate in an environmental health literacy course will have a higher environmental health literacy score based on quantitative questionnaire evaluation post-course compared to pre-course. Hypothesis 1b. Doula... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/25/2025
Locations: Harvard T.H. Chan School of Public Health, Boston, Massachusetts
Conditions: Health Knowledge, Attitudes, Practice
Expressive Writing on Minority Stressors Among Sexual Minority Veterans
Recruiting
Sexual minority stressors (e.g., sexual minority identity-based discrimination) contribute to greater risk for and severity of depression, anxiety, substance use disorders and suicide among sexual minority Veterans. However, no brief, scalable, one-on-one interventions targeting sexual minority stressor-related distress are available in Veterans Affairs (VA) for sexual minority Veterans. The proposed research will examine the feasibility, acceptability, and preliminary effectiveness of a brief,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: Depressive Symptoms, Anxiety
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Recruiting
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Mass General Hospital (MGH), Boston, Massachusetts
Conditions: Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
A Study of NB003 in Patients with Advanced Malignancies
Recruiting
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
Recruiting
Our overall objective is to obtain an initial assessment of the potential value of using \[18F\]3F4AP for imaging demyelinating diseases such as multiple sclerosis: * Aim 1) Assess the safety of \[18F\]3F4AP in healthy volunteers and subjects with multiple sclerosis (MS). Hypothesis 1: Administration of \[18F\]3F4AP will result in no changes in vitals or other adverse events. * Aim 2) Assess the pharmacokinetics of a bolus infusion of \[18F\]3F4AP in humans including healthy volunteers and MS p... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/25/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Sclerosis
Minority Barriers in Anesthesia
Recruiting
The investigators aim to survey members of the ASA (medical students, residents, and attendings) who self-identify as minorities to assess if there are systemic barriers to minorities pursuing leadership positions. The investigators hypothesize that structural issues such as a lack of formalized mentoring programs play a role in reduced minority professional advancement.
Gender:
ALL
Ages:
Between 25 years and 75 years
Trial Updated:
02/25/2025
Locations: Iwona Bonney, Boston, Massachusetts
Conditions: Minority Barrier, Lack of Mentoring Program, Pass Over for Promotion
Amplatzer Amulet LAAO Vs. NOAC
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Atrial Fibrillation, Stroke, Bleeding
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Recruiting
This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant ("bone marrow transplant"). The goal of this research study is to (1) test the safety of adding the study drug, Venetoclax, to a standard of care conditioning regimen for bone mar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
Recruiting
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Acute Kidney Injury
Study of Xiflamâ„¢ Treatment in Patients Post COVID-19 Infection Suffering from What is Known As Long COVID (LC)
Recruiting
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID. Xiflam (n=10) or placebo (n=5) will be administered orally once a day (QD) for 12 weeks.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/24/2025
Locations: Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts
Conditions: Long COVID